IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
Metrics to compare | 287840 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship287840PeersSector | |
|---|---|---|---|---|
P/E Ratio | −78.8x | −12.4x | −0.6x | |
PEG Ratio | −6.37 | −0.34 | 0.00 | |
Price/Book | 34.2x | 3.3x | 2.6x | |
Price / LTM Sales | 489.2x | 19.5x | 3.4x | |
Upside (Analyst Target) | - | 353.0% | 41.1% | |
Fair Value Upside | Unlock | 17.8% | 5.3% | Unlock |